Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Non-Current ReceivablesReceivables - NetReceivables - OtherReceivables Refunds
Ratios

Ascendis Pharma A (ASND) Non-Current Receivables (2019 - 2025)

Ascendis Pharma A (ASND) has disclosed Non-Current Receivables for 7 consecutive years, with $12.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Receivables rose 411.05% to $12.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.7 million through Dec 2025, up 411.05% year-over-year, with the annual reading at $12.7 million for FY2025, 411.05% up from the prior year.
  • Non-Current Receivables hit $12.7 million in Q4 2025 for Ascendis Pharma A, up from $2.5 million in the prior quarter.
  • In the past five years, Non-Current Receivables ranged from a high of $12.7 million in Q4 2025 to a low of $2.0 million in Q4 2022.
  • Historically, Non-Current Receivables has averaged $4.3 million across 5 years, with a median of $2.3 million in 2023.
  • Biggest five-year swings in Non-Current Receivables: decreased 5.29% in 2022 and later soared 411.05% in 2025.
  • Year by year, Non-Current Receivables stood at $2.1 million in 2021, then dropped by 5.29% to $2.0 million in 2022, then rose by 16.83% to $2.3 million in 2023, then increased by 8.19% to $2.5 million in 2024, then skyrocketed by 411.05% to $12.7 million in 2025.
  • Business Quant data shows Non-Current Receivables for ASND at $12.7 million in Q4 2025, $2.5 million in Q4 2024, and $2.3 million in Q4 2023.